Assessment of Gamma-Radiation Levels in Selected Oil Spilled Areas in Rivers State, Nigeria

A prelude radiological impact assessment of oil spillage on the oil spilled environment, those saddled with the responsibility of cleaning the spilled crude and the host/nearest communities residents in Rivers State Nigeria has been examined in-situ, using radiation meters (Digilert 100 nuclear radiation meter) and a geographical positioning system (GPS). Readings were taken twice in a month for three months in the five different oil spilled site and one measurement taken at a control site where there is no oil spillage but within oil bearing community. The average radiation values in all the oil spilled site is 0.019±0.006mRh-1, this is far above the 0.011±0.003mRh-1obtained for the control and ICRP 0.013±0.005mRh-1 world background levels. The average equivalent dose rate obtained in all the five studied site is 1.6mSvy-1 while the dose rate in the control is 0.93mSvy-1. The results showed that all the oil spilled sites yearly equivalent dose rate exceeded the 1mSvy-1 maximum permissible limit recommend for the public and non-nuclear industrial environment by International Council on Radiological Protection (ICRP,1999). All the oil spilled environment radiation levels exceeded the normal world average BIR level of 0.013mRh-1and other reported values in similar environment. This shows that the oil spilled environment have been impacted radiologically. This will pose some long-term health side effects on the clean-up workers and residents of the host communities. Interim proactive measures are recommended while further and a detail study is ongoing

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)